Changes of serum cytokines in hyperthyroid graves' disease patients at diagnosis and during methimazole treatment

NeuroImmunoModulation

Volumn 18, Issue 1, 2010, Pages 45-51

  Pedro, Ana Beatriz B ^a   Romaldini, João H ^a   Takei, Kyoko ^a  

^a PONTIFÍCIA UNIVERSIDADE CATÓLICA DE CAMPINAS   (Brazil)

Author keywords

Autoimmunity; Cytokines; Graves' disease; Hyperthyroidism

Indexed keywords

CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 5; INTERLEUKIN 6; LIOTHYRONINE; SOLUBLE INTERLEUKIN 2 RECEPTOR; THIAMAZOLE; THYROTROPIN RECEPTOR ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOCRINE OPHTHALMOPATHY; EUTHYROIDISM; FEMALE; GRAVES DISEASE; HUMAN; IMMUNOMODULATION; LIOTHYRONINE BLOOD LEVEL; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL;

ADOLESCENT; ADULT; ANTITHYROID AGENTS; CYTOKINES; FEMALE; GRAVES DISEASE; GRAVES OPHTHALMOPATHY; HUMANS; MALE; METHIMAZOLE; MIDDLE AGED; THYROID FUNCTION TESTS; YOUNG ADULT;

EID: 77954407587     PISSN: 10217401     EISSN: None     Source Type: Journal    
DOI: 10.1159/000311519     Document Type: Article

References (36)

1. Camacho-Arroyo I, López-Griego L, Mo-rales-Montor J: The role of cytokines in the regulation of neurotransmission. Neuroim-munomodulation 2009; 16:1-12.
2. Aijan RA, Weetman AP: Cytokine in thyroid autoimmunity. Autoimmunity 2003; 36: 351-359.
3. Celik I, Akalin S, Erbas T: Serum level of IL 6 and tumor necrosis factor-alpha in hyper-thyroid patients before and after propylthio-uracil treatment. Eur J Endocrinol 1995; 132: 668-772.
4. Miyauchi S, Matsuura B, Onji M: Increased levels of serum IL-18 in Graves' disease. Thy-roid 2000; 10: 815-819.
5. Díez JJ, Hernanz A, Medina S, Bayón C, Igle-sias P: Serum concentration of tumor necro-sis factor-alpha (TNF-alpha) and soluble TNF-alpha receptor p55 in patients with hy-pothyroidism and hyperthyroidism before and after normalization of thyroid function. Clin Endocrinol 2002; 57: 515-521.
6. Komiya I, Amada T, Sato A, Kouki T, Nishi-mori T, Takasu N: Remission and recurrence of hyperthyroid Graves' disease during and after methimazole treatment when assessed by IgE and IL-13. J Clin Endocrinol Metab 2001; 86: 3549-3554.
7. Hidaka Y, Motoshi O, Shimaoka Y, Takeoka K, Tada H, Amino M: Increased serum con-centration of IL-5 in patients with Graves' disease and Hashimoto's thyroiditis. Thy-roid 1998; 8: 235-239.
8. Kocjan T, Wraber B, Kocijanic A, Hojkers H: Methimazole upregulates T-cell-cytokines without the existing Th1/Th2 imbalance in Graves' disease. J Endocrinol Invest 2004; 27: 302-307.
9. Siddiqi A, Monson JP, Wood DF, Besser GM, Burrin JM: Serum cytokines in thyrotoxico-sis. J Clin Endocrinol Metab 1999; 84:435-439.
10. Salvi M, Girasole G, Pedrazzoni M, Giuliani N, Minelli R, Braverman LE, Roti E: In-creased serum concentrations if IL-6 and soluble IL-6 receptor in patients with Graves' disease. J Clin Endocrinol Metab 1996; 81: 2976-2979.
11. Tsatsoulis P, Vlachoyiannopoulos PG, Dalekos GN, Johnson EO, Moutsopoulos HM: Increased serum IL-1 beta during treat-ment of hyperthyroidism with antithyroid drugs. Eur J Clin Invest 1995; 25:654-658.
12. Chow CC, Lai KN, Leung JCK, Chan JCN, Cockram CS: Serum soluble IL 2 receptor in hyperthyroid Graves' disease and effect of carbimazole therapy. Clin Endocrinol 1990; 33:317-321.
13. Salvi M, Pedrazzoni M, Girasole G, Giuliani N, Minelli R, Wall JR, Roit E: Serum concen-trations of proinflammatory cytokines in Graves' disease: effect of treatment thyroid function ophthalmopathy and cigarette smoking. Eur J Endocrinol 2000; 143: 197-202.
14. Chopra IJ, Sakane S, Teco GNC: A study of serum concentration of tumor necrosis factoralpha in thyroidal and nonthyroidal ill-nesses. J Clin Endocrinol Metab 1991; 72: 1113-1116.
15. Yamada T, Komiya I, Miyahara Y, Komatsu M, Shima I, Inazawa T, Aizawa T: Effect of methimazole treatment for 2 years on circu-lating IL-4, IgE, TBII, and TSAb in patients with hyperthyroid Graves' disease. Endocr J 2006; 53: 783-788.
16. Phenekos C, Vryonidou A, Gritzapis AD, Baxevanis CN, Goula M, Papamichail M: Th1 and Th2 serum cytokines profiles char-acterize patients with Hashimoto's thyroid-itis (Th1) and Graves' disease (Th2). Neuro-immunomodulation 2004; 11:209-213.
17. Bossowski A, Urban M: Serum levels of cy-tokines in children and adolescents with Graves' disease and non-toxic nodular goi-ter. J Pediatr Endocrinol Metab 2001; 14:741-747.
18. Molnár I: The balance shift in Th1/Th2 re-lated IL-12/IL-5 cytokines in Graves' disease during methimazole therapy. Autoimmuni-ty 2007; 40:31-37.
19. Tamuru M, Matsuura B, Onji M: Increased levels of serum IL-12 in Graves' disease. Eur J Endocrinol 1999; 141:111-116.
20. Weetman AP, Tandon N, Morgan BP: Anti-thyroid drugs and release of inflammatory mediators by complement-attacked thyroid cells. Lancet 1992; 340:633-636.
21. Crescioli C, Cosmi L, Borgogni E, Santarlasci V, Gelmini S, Sottili M, Sarchielli E, Annunziato F, Serio M: Methimazole inhibits CXC chemokine ligand 10 secretion in hu-man thyrocytes. J Endocrinol 2007; 195: 145-155.
22. Nakanishi K, Tanigushi Y, Ohta Y: Increased soluble IL 2 receptor levels in autoimmune thyroid disease. Acta Endocrinol 1991; 125: 253-258.
23. Koukkou E, Panayiotidis P, Alevizou-Terza-ki V, Thalassinos N: High levels of serum sol-uble IL-2 receptor in hyperthyroid patients: correlation with serum thyroid hormones and independence from the etiology of the hyperthyroidism. J Clin Endocrinol Metab 1991; 73: 771-776.
24. Mariotti S, Caturegli P, Barbesino G, Marinò M, Del Prete GF, Chiovato L, Tonacchera M, De Carli MD, Pinchera A: Thyroid function and thyroid immunity independently mod-ulate serum concentration of soluble inter-leukin 2 (IL-2) receptor (sIL-2R) in thyroid disease. Clin Endocrinol 1992; 37: 415-422.
25. Guo J, Rapoport B, McLachlan SM: Balance Th1/Th2 cytokines in thyroid autoantibody synthesis in vitro. Autoimmunity 1999; 30: 1-9.
26. Wakelkamp IMMJ, Gerding MN, Van Der Meer JWC, Prummel MF, Wiersinga WM: Both Th1-and Th2-derived cytokines in se-rum are elevated in Graves' ophthalmopa-thy. Clin Exp Immunol 2000; 121:453-457.
27. Ajjan RA, Weetman AP: New understanding of the role of cytokines in the pathogenesis of Graves' ophthalmopathy. J Endocrinol In-vest 2004; 27: 237-245.
28. Hidaka Y, Massai T, Sumizaki H, Takeoka K, Tada H, Amino M: Onset of Graves' thyro-toxicosis after an attack of allergic rhinitis. Thyroid 1996; 6: 347-351.
29. Yamada T, Sato A, Komiya I, Nishimori T, Ito Y, Terão A, Eto S, Tanaka Y: An elevation of serum immunoglobulin E provides a new as-pect of hyperthyroidism Graves' disease. J Clin Endocrinol Metab 2000; 85:2775-2778.
30. Bartalena L, Grasso L, Brogioni S, Aghini-Lombardi F, Braverman LE, Martino E: Se-rum interleukin-6 in amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab 1994; 78: 423-427.
31. Pichler R, Maschek W, Hatzl-Griesenhofer M, Hubber H, Crespillo-Gómez C, Berg J: Soluble tumor necrosis factor alpha receptor I and IL-6 as markers of activity in thyro-toxic Graves' disease. Horm Metab Res 2003; 35: 427-433.
32. Cooper DS: Drug therapy: antithyroid drug. N Engl J Med 2005; 352: 905-917.
33. Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Tørring O: TSH-re-ceptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective random-ized study. Eur J Endocrinol 2008; 158: 69-75.
34. Antonelli A, Rotondi M, Fallahi P, Roma-gnani P, Ferrari SM, Barani L, Ferrannini E, Serio M: Increase of interferon-gamma-in-ducible CXC chemokine CXCL10 serum lev-els in patients with active Graves' disease, and modulation by methimazole therapy. Clin Endocrinol 2006; 64: 189-195.
35. Zantut-Wittmann DE, Tambascia MA, Trevisan MAS, Pinto GA, Vassallo J: Anti-thyroid drugs inhibit in vivo HLA-DR ex-pression in thyroid follicular cells in Graves' disease. Thyroid 2001; 11: 575-580.
36. Botella-Carretero JI, Prados A, Manzano L, Montero MT, Escribano L, Sancho J, Esco-bar-Morreale HF: The effects of thyroid hor-mones on circulation markers of cell-medi-ated immune response, as studied in patients with differentiated thyroid carcinoma before and during thyroxine withdrawal. Eur J En-docrinol 2005; 153: 223-230.